Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Lieberman

Showing results (321-330 of 345) with videos related to

Pageof 35
Sort By:
Neuro-Oncology Advances|October 7, 2024
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastomaMatthias Holdhoff, Xiaobu Ye, Roy E Strowd, et al.
Neuro-Oncology|June 19, 2008
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor ConsortiumSusan M Chang, Kathleen R Lamborn, John G Kuhn, et al.
Journal of Neuro-Oncology|October 29, 2015
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group studyH Ian Robins, Peixin Zhang, Mark R Gilbert, et al.
Neuro-Oncology|August 15, 2014
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patientsElizabeth Vera-Bolanos, Kenneth Aldape, Ying Yuan, et al.
Neuro-Oncology Practice|December 14, 2019
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525H Ian Robins, Jens Eickhoff, Mark R Gilbert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2016
Repeatability of <sup>18</sup>F-FLT PET in a Multicenter Study of Patients with High-Grade GliomaMartin A Lodge, Matthias Holdhoff, Jeffrey P Leal, et al.
Journal of Translational Medicine|December 21, 2007
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomasHideho Okada, Frank S Lieberman, Kevin A Walter, et al.
Neuro-Oncology|August 5, 2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Jennifer L Clarke, Michele M Ennis, W K Alfred Yung, et al.
Neuro-Oncology|February 21, 2018
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group databaseDeborah T Blumenthal, Minhee Won, Minesh P Mehta, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastomaPhioanh Leia Nghiemphu, Patrick Y Wen, Kathleen R Lamborn, et al.
Pageof 35

Showing results (321-330 of 345) with videos related to

Sort By:
Pageof 35
Neuro-Oncology Advances|October 7, 2024
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastomaMatthias Holdhoff, Xiaobu Ye, Roy E Strowd, et al.
Neuro-Oncology|June 19, 2008
Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor ConsortiumSusan M Chang, Kathleen R Lamborn, John G Kuhn, et al.
Journal of Neuro-Oncology|October 29, 2015
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group studyH Ian Robins, Peixin Zhang, Mark R Gilbert, et al.
Neuro-Oncology|August 15, 2014
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patientsElizabeth Vera-Bolanos, Kenneth Aldape, Ying Yuan, et al.
Neuro-Oncology Practice|December 14, 2019
The association between BMI and BSA-temozolomide-induced myelosuppression toxicities: a correlative analysis of NRG oncology RTOG 0525H Ian Robins, Jens Eickhoff, Mark R Gilbert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 1, 2016
Repeatability of <sup>18</sup>F-FLT PET in a Multicenter Study of Patients with High-Grade GliomaMartin A Lodge, Matthias Holdhoff, Jeffrey P Leal, et al.
Journal of Translational Medicine|December 21, 2007
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomasHideho Okada, Frank S Lieberman, Kevin A Walter, et al.
Neuro-Oncology|August 5, 2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Jennifer L Clarke, Michele M Ennis, W K Alfred Yung, et al.
Neuro-Oncology|February 21, 2018
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group databaseDeborah T Blumenthal, Minhee Won, Minesh P Mehta, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2010
A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastomaPhioanh Leia Nghiemphu, Patrick Y Wen, Kathleen R Lamborn, et al.
Pageof 35